EVAH 90

Main information

  • Trade name:
  • EVAH 90 10 TAB
  • Pharmaceutical form:
  • TAB
  • Composition:
  • 10
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • EVAH 90 10 TAB
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

9-4-2018

Club 13 Recalls Kratom Maeng Da Red Powder and Capsules Because of Possible Health Risk

Club 13 Recalls Kratom Maeng Da Red Powder and Capsules Because of Possible Health Risk

Club 13 of St. Augustine, FL is recalling 15-gram, 30-gram, 90-gram, 150-gram, and 454-gram pouches, and all bulk orders of "Maeng Da Red" kratom powder; and 5-count, 25-count, 50-count, 100-count, 120-count capsule, and all bulk capsule orders of “Maeng Da Red” kratom bottles; and 5-count, 20-count, 25-count, 40-count, 50-count capsule “Maeng Da Red XS” kratom bottles because they have the potential to be contaminated with Salmonella , an organism which can cause serious and sometimes fatal infections i...

FDA - U.S. Food and Drug Administration

19-10-2017

ANSES's recommendations for implementing national surveillance of pesticides in ambient air

ANSES's recommendations for implementing national surveillance of pesticides in ambient air

Today ANSES is publishing the results of its collective expert appraisal aimed at proposing arrangements for implementing national surveillance of pesticides in ambient air in metropolitan France and the overseas départements and regions (DROM). Based on a list of 90 priority substances, this national surveillance should make it possible to assess the chronic exposure of the general population and the associated health risks. Language English

France - Agence Nationale du Médicament Vétérinaire

29-6-2017

FDA unveils plan to eliminate orphan designation backlog

FDA unveils plan to eliminate orphan designation backlog

Today, the U.S. Food and Drug Administration unveiled a strategic plan to eliminate the agency’s existing orphan designation request backlog and ensure continued timely response to all new requests for designation with firm deadlines. The agency’s Orphan Drug Modernization Plan comes a week after FDA Commissioner Scott Gottlieb committed to eliminating the backlog within 90 days and responding to all new requests for designation within 90 days of receipt during his testimony before a Senate subcommittee.

FDA - U.S. Food and Drug Administration

15-6-2017

Teva Pharmaceuticals, USA Extends Voluntary Nationwide Recall to Consumer/User Level for One Lot of Paliperidone Extended-Release Tablets, 3mg, 90 Count Bottles Distributed Under the Actavis Pharma Inc. Label Due to Dissolution Test Failure

Teva Pharmaceuticals, USA Extends Voluntary Nationwide Recall to Consumer/User Level for One Lot of Paliperidone Extended-Release Tablets, 3mg, 90 Count Bottles Distributed Under the Actavis Pharma Inc. Label Due to Dissolution Test Failure

Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles that was distributed under the Actavis Pharma Inc. label. In coordination with FDA, Teva is extending this recall to the CONSUMER/USER level.

FDA - U.S. Food and Drug Administration

26-5-2017

Astrazeneca Initiates Voluntary Nationwide Recall of One Lot of Brilinta 90 mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle From That Lot

Astrazeneca Initiates Voluntary Nationwide Recall of One Lot of Brilinta 90 mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle From That Lot

AstraZeneca today announced that the Company is notifying physicians and consumers that it is voluntarily recalling one lot of professional (physician) sample bottles containing eight tablets of BRILINTA (ticagrelor) 90mg tablets as a precautionary measure. This voluntary recall follows a report that a professional sample bottle containing eight tablets of BRILINTA 90mg also contained another medicine called ZURAMPIC (lesinurad) 200 mg tablets which is also manufactured by AstraZeneca.

FDA - U.S. Food and Drug Administration

26-5-2017

Brilinta (ticagrelor) 90 mg tablets, 8-count Physician Sample Bottles: Recall of Lot # JB5047 - Due to Report of Another Medicine in One Bottle

Brilinta (ticagrelor) 90 mg tablets, 8-count Physician Sample Bottles: Recall of Lot # JB5047 - Due to Report of Another Medicine in One Bottle

Unintentional dosing with Zurampic has the potential to lead to adverse renal effects including acute renal failure.

FDA - U.S. Food and Drug Administration

19-5-2017

Dynamic Technical Formulations, LLC. Issues a Voluntary Nationwide Recall of Tri-Ton Due to the Presence of Andarine and Ostarine

Dynamic Technical Formulations, LLC. Issues a Voluntary Nationwide Recall of Tri-Ton Due to the Presence of Andarine and Ostarine

Dynamic Technical Formulations LLC. is voluntarily recalling all lots of Tri-Ton. This product was sold in 90 count bottles as a dietary supplement and includes all lot number and expiration dates of the product. The US Food and Drug Administration (FDA) lab analysis of Tri-Ton was found to contain andarine and ostarine which are selective androgen receptor modulators (SARMs) that are considered unapproved drugs and anabolic steroid-like substances.

FDA - U.S. Food and Drug Administration

16-4-2018

Extavia (Novartis Europharm Limited)

Extavia (Novartis Europharm Limited)

Extavia (Active substance: Interferon beta-1b) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2321 of Mon, 16 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/933/T/90

Europe -DG Health and Food Safety

21-3-2018

Freezing Hunger-Signaling Nerve May Spur Weight Loss

Freezing Hunger-Signaling Nerve May Spur Weight Loss

Freezing the posterior vagal trunk nerve using a minimally invasive, percutaneous technique significantly reduces appetite and results in substantial weight loss at 90 days, a small pilot study suggests.

US - RxList

31-1-2018

Scientific guideline:  Draft ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, draft: consultation open

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EMA - European Medicines Agency

26-1-2018

CLORPACTIN WCS-90 (Chlorine) Powder, For Solution [United-Guardian, Inc.]

CLORPACTIN WCS-90 (Chlorine) Powder, For Solution [United-Guardian, Inc.]

Updated Date: Jan 26, 2018 EST

US - DailyMed

1-12-2017

AIR 90% CARBON DIOXIDE 10% Gas [A-OX WELDING SUPPLY CO., INC.]

AIR 90% CARBON DIOXIDE 10% Gas [A-OX WELDING SUPPLY CO., INC.]

Updated Date: Dec 1, 2017 EST

US - DailyMed

27-10-2017

NP THYROID 90 (Levothyroxine, Liothyronine) Tablet [Acella Pharmaceuticals, LLC]

NP THYROID 90 (Levothyroxine, Liothyronine) Tablet [Acella Pharmaceuticals, LLC]

Updated Date: Oct 27, 2017 EST

US - DailyMed

16-10-2017

COMPRESSO PAP 90 CPF Powder [Granules India Limited]

COMPRESSO PAP 90 CPF Powder [Granules India Limited]

Updated Date: Oct 16, 2017 EST

US - DailyMed

13-10-2017

NP THYROID 90 (Levothyroxine, Liothyronine) Tablet [Preferred Pharmaceuticals Inc.]

NP THYROID 90 (Levothyroxine, Liothyronine) Tablet [Preferred Pharmaceuticals Inc.]

Updated Date: Oct 13, 2017 EST

US - DailyMed

11-10-2017

Community Cancer Care 'Much Cheaper' Than Hospital

Community Cancer Care 'Much Cheaper' Than Hospital

Cancer care is significantly more expensive when delivered in a hospital outpatient setting than in a community oncology practice. A new study shows that it cost almost 60% more, or $90,144 per year, for a patient to receive chemotherapy in the hospital, and patients who received treatment in the hospital setting were more likely to visit the emergency department after treatment.

US - RxList